Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.
ABSTRACT Therapeutic action of selective serotonin reuptake inhibitors (SSRIs) is delayed from 8 to 12 weeks in patients with obsessive-compulsive disorder (OCD). Several different agents have been tested to reduce the SSRI therapeutic latency time. Mirtazapine, an antagonist at alpha2-adrenoceptors, does not enhance serotonin (5-HT) neurotransmission directly but disinhibits the norepinephrine activation of 5-HT neurons and thereby increases 5-HT neurotransmission by a mechanism that may not require a time-dependent desensitization of receptors. The present study was undertaken to determine whether the mirtazapine-citalopram combination could induce an earlier and/or greater effect on the 5-HT system in OCD subjects than citalopram alone.
Forty-nine patients with OCD (DSM-IV) without comorbid depression were randomly assigned to a 2-tailed, single-blind, 12-week clinical trial with citalopram (20-80 mg/day) plus placebo or citalopram plus mirtazapine (15-30 mg/day). Assessments were performed weekly with the Yale-Brown Obsessive Compulsive Scale (YBOCS), the Hamilton Rating Scale for Depression, and the Clinical Global Impressions scale. Data were collected from November 2001 to July 2003.
The citalopram plus mirtazapine group achieved a reduction of at least 35% in YBOCS score and a "much improved" or "very much improved" rating on the Clinical Global Impressions-Improvement scale from the fourth week, while the citalopram plus placebo group obtained these results only from the eighth week. The number of responders was higher in the citalopram plus mirtazapine group at the fourth week of treatment, while no difference between groups in the response rate was noted at the eighth and twelfth weeks of treatment.
We found an earlier onset of response action in OCD symptoms and reduced undesired side effects when mirtazapine was added to citalopram. This augmentation strategy deserves clinical and research consideration through further double-blind, placebo-controlled studies.
SourceAvailable from: Bradley Gaynes
[Show abstract] [Hide abstract]
ABSTRACT: Anxiety and related disorders are among the most common mental disorders, with lifetime prevalence reportedly as high as 31%. Unfortunately, anxiety disorders are under-diagnosed and under-treated.BMC Psychiatry 07/2014; 14(Suppl 1):S1. DOI:10.1186/1471-244X-14-S1-S1 · 2.24 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: La mirtazapina es un antidepresivo con buena eficacia y pocos efectos adversos, pero también se ha señalado que ataca los síntomas de ansiedad en pacientes deprimidos. Se ha considerado que su mecanismo principal de acción para explicar esta eficacia es la mejora simultánea de la transmisión noradrenérgica y serotoninérgica. Debido a los efectos adversos que se presentan a menudo con los inhibidores selectivos de la recaptación de serotonina (ISRS) o con los antidepresivos tricíclicos (ATC) usados para tratar el trastorno de pánico, se ha usado mirtazapina en algunos estudios abiertos. Se discuten los resultados de estos estudios, principalmente los que comparan mirtazapina con los ISRS (fluoxetina, paroxetina), en cuanto a eficacia y tolerancia.12/2006; 13(6):204-210. DOI:10.1016/S1134-5934(06)75364-7